Zhejiang Taimei Medical Technology Co Ltd Class H (2576) AI Stock Analysis

Zhejiang Taimei Medical Technology Co Ltd Class H

(HKEX:2576)

Select Model

Rating:43Neutral

Price Target:HKD 4.00▼(-3.38% Downside)

Action:reiterated

Date:10/08/26

The overall score is driven primarily by weak financial quality: despite rapid revenue growth and a solid gross margin, the company continues to post losses and burn cash, creating meaningful profitability and liquidity risk. Technical signals are mixed but lean slightly negative as the price trades below key medium-term averages and MACD is negative, with neutral momentum indicators preventing a worse technical score. Valuation is constrained by a sizable negative P/E ratio and lack of dividends, so potential upside rests on future earnings improvements rather than current fundamentals.

Positive Factors

Operational improvementThe sharp 2025 revenue rebound, higher gross margin, and materially narrower loss indicate meaningful operational progress. If this improvement persists, greater scale and better economics could support a credible path toward profitability and strengthen the company’s ability to fund future growth.

Negative Factors

Unproven profitabilityThe business has not yet demonstrated sustainable profitability despite improved margins and narrower losses. Negative operating earnings limit internally generated funding, make the turnaround dependent on further execution, and leave earnings power vulnerable if the recent improvement does not persist.

Zhejiang Taimei Medical Technology Co Ltd Class H (2576) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 2.29B
Dividend Yield: ―
Average Volume (3M): 501.54K
Price to Earnings (P/E): -30.3
Beta (1Y): 1.03
Revenue Growth: ―
EPS Growth: ―
Country: Hong Kong
Employees: 687
Sector: General
Sector Strength: 55
Industry: Software - Application

Zhejiang Taimei Medical Technology Co Ltd Class H Business Overview & Revenue Model

Company Description

Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The comp...

Zhejiang Taimei Medical Technology Co Ltd Class H Financial Statement Overview

Summary

Strong 278% revenue growth to 499M and a solid 42% gross margin show improving scale, but persistent net losses, weak profit margins (-8%), negative EBIT, and sustained negative operating and free cash flows (-39M and -43M) with -62% free cash flow growth indicate ongoing profitability and liquidity risks.

Income Statement

35Negative

Balance Sheet

65Positive

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	531.96M	499.28M	551.16M	573.14M	549.22M	466.18M
Gross Profit	235.10M	211.91M	224.94M	179.00M	185.40M	163.59M
EBITDA	-61.75M	-28.60M	-176.73M	-302.97M	-364.38M	-440.39M
Net Income	-65.15M	-41.74M	-214.61M	-346.78M	-412.91M	-479.61M
Balance Sheet
Total Assets	1.50B	1.56B	1.58B	1.44B	1.83B	1.80B
Cash, Cash Equivalents and Short-Term Investments	1.08B	1.19B	1.20B	1.07B	1.41B	1.40B
Total Debt	85.39M	61.16M	34.76M	28.64M	81.47M	77.44M
Total Liabilities	348.40M	365.62M	348.62M	402.56M	441.97M	393.75M
Stockholders Equity	1.08B	1.12B	1.16B	978.33M	1.31B	1.41B
Cash Flow
Free Cash Flow	-26.87M	-43.15M	-207.30M	-360.64M	-357.44M	-249.94M
Operating Cash Flow	-23.75M	-39.38M	-201.62M	-351.16M	-329.22M	-217.53M
Investing Cash Flow	284.09M	328.99M	-283.68M	237.69M	-5.88M	-379.35M
Financing Cash Flow	49.11M	24.90M	281.04M	-39.28M	285.59M	-40.08M

Zhejiang Taimei Medical Technology Co Ltd Class H Technical Analysis

Technical Analysis SentimentNegative

Last Price4.14

Price Trends

50DMA4.84Negative

100DMA5.32Negative

200DMA4.97Negative

Market Momentum

MACD-0.17Positive

RSI35.44Neutral

STOCH48.54Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2576, the sentiment is Negative. The current price of 4.14 is below the 20-day moving average (MA) of 4.48, below the 50-day MA of 4.84, and below the 200-day MA of 4.97, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 35.44 is Neutral, neither overbought nor oversold. The STOCH value of 48.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2576.

Zhejiang Taimei Medical Technology Co Ltd Class H Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

HK:2576 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:1450	70Outperform	HKD 640.28M	4.36	21.83%	10.99%	35.78%	131.58%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
HK:8148	50Neutral	HKD 1.49B	82.44	21.60%	―	151.97%	―
HK:2576	43Neutral	HKD 2.33B	-30.33	-5.91%	―	―	―
HK:8156	43Neutral	HKD 122.94M	-7.38	20.88%	―	-25.58%	-12.50%

* General Sector Average

Performance Comparison

HK:2576 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:2576	Zhejiang Taimei Medical Technology Co Ltd Class H	4.14	-0.28	-6.33%
HK:1450	Century Sage Scientific Holdings Ltd	0.46	-0.57	-55.44%
HK:8148	Aurum Pacific (China) Group Ltd.	3.25	1.22	60.10%
HK:8156	Sinopharm Tech Holdings Limited	0.19	-0.11	-35.33%

Zhejiang Taimei Medical Technology Co Ltd Class H Corporate Events

Zhejiang Taimei Posts Higher Revenue but Wider Interim Loss

Aug 26, 2026

Zhejiang Taimei Medical Technology reported revenue of RMB263.6 million for the six months ended June 30, 2026, an 8% increase year-on-year, with gross profit rising 17.5% and margin improving to 44.7%. Despite higher sales and other income, the Grou...

Zhejiang Taimei Schedules Board Meeting to Approve Interim Results and Mull Dividend

Aug 14, 2026

Zhejiang Taimei Medical Technology Co., Ltd. has scheduled a board meeting for August 26, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The board will also cons...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 08, 2026

Zhejiang Taimei Medical Technology Co Ltd Class H AI Stock Analysis